Announced Thu, 30 Apr · 23:56 IST

Please take on record the appointment of Mr. Sanat Bhat and Mr. Vinay Pandey as Directors and appointment of Mr. Sharad Kathawate as the Chief Financial Officer of the Company w.e.f. 01-05-2026.

Management Changes View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+2.4%1-day move
₹30.26
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+2.4-0.8-0.8+0.1-0.5-0.9+14.0+13.9+31.8
Up moveDown movePending
AI summary

Sudarshan Pharma Industries has announced three key leadership appointments effective 1st May 2026. Mr. Sanat Bhat, a Chartered Accountant with 13+ years of experience in Transaction Advisory, Investment Banking, and Corporate Governance, joins as an Additional Independent Director. Dr. Vinay Pandey, a geotechnical expert with 24+ years of experience in infrastructure projects including Mumbai Metro Line 3 and India's bullet train, joins as a Non-Executive Director. Mr. Sharad Kathawate, a qualified M.Com, LLB, CA, MBA (Finance), and CS (Final) with 25+ years of finance leadership experience, has been appointed as Chief Financial Officer. All three appointees have confirmed they are not related to any existing directors of the Company.

Likely market impact

The appointment of experienced professionals to the board and CFO role suggests the company is strengthening its governance and financial oversight. These additions could be viewed positively by investors as they bring diverse expertise in finance, infrastructure, and corporate governance.